Thursday, September 17, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Trialsnt-0796semaglutiderezeraobesity

Rezera completes Phase 2a of NT-0796 added to semaglutide

The six-month placebo-controlled obesity study of the NLRP3 inhibitor, formerly run by NodThera, is listed as completed.

PR
By Priya Raman · Science Reporter
Sep 17 08:00 ETSource: ClinicalTrials.gov

The wire

  1. 01RESOLVE-2 tested NT-0796 as an adjunct to semaglutide in obesity over six months; status is completed.
  2. 02Combination approaches aim to build on GLP-1 weight loss.
  3. 03Results have not been reported in the listing.

From the source

Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)

NCT07220629 · PHASE2 · COMPLETED · Sponsor: Rezera (formerly NodThera Limited) · Conditions: Obesity. A Phase 2a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to explore the safety and efficacy of NT-0796 as an adjunct to semaglutide in participants with obesity over a 6 months treatment period.

Read at clinicaltrials.gov
Source URL https://clinicaltrials.gov/study/NCT07220629